Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics Limited has received approval from the Bellberry Human Research Ethics Committee in Australia to initiate a Phase 1 clinical trial for its radiotherapeutic, RAD 402, targeting advanced prostate cancer. This trial marks a significant milestone as it is the first company-sponsored therapeutic trial using the radionuclide 161 Tb. The approval underscores the potential of RAD 402, which has shown promising preclinical results in targeting tumors with limited bone and marrow uptake, offering a novel mechanism for treating prostate cancer.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company specializing in the development of innovative radiopharmaceutical products for oncology. The company focuses on areas with high unmet medical needs and is listed on both the ASX and NASDAQ. Radiopharm’s pipeline includes a variety of platform technologies and clinical trials targeting solid tumor cancers such as lung, breast, and brain metastases.
Average Trading Volume: 6,526,243
Technical Sentiment Signal: Sell
Current Market Cap: A$61.17M
Learn more about RAD stock on TipRanks’ Stock Analysis page.